Clinical Relevance Of Individual Response To Iron Chelation Therapy (Ict) In Patients With Myelodysplastic Syndromes (Mds) And Transfusion Requirement

Background Deferasirox (DFX) is widely employed as iron chelation therapy (ICT) in the current clinical practice in patients with myelodysplastic syndromes (MDS) and chronic transfusion need. The efficacy of DFX in reducing median ferritin levels in different cohorts of these patients has been reported in many trials, but the lack of worldwide accepted criteria of individual response to ICT makes it difficult to appreciate its clinical relevance for any single patient.